0 CHECKOUT

PRODUCT FILTERS

REGION

14
14
14
4

COUNTRY

14

CATEGORIES

  • 27
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

7
29
30
33

PUBLISHED

0
1
4
33

PRODUCT TYPE

21
5
3
2
1
1

Search for: "BioMarin Pharmaceutical Inc-Deals & Alliances Report"

BioMarin Pharmaceutical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

The Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization...

Published:  March 2016
Price:  From

BioMarin Pharmaceutical Inc. - SWOT, Strategy and Corporate Finance Report

BioMarin Pharmaceutical Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis,...

Published:  November 2013
Price:  From

BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011

BioMarin Pharmaceutical Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “BioMarin Pharmaceutical Inc. - Product Pipeline Review - H2 2011” provides...

Published:  November 2011
Price:  From

Global Gene Therapy Partnering Terms and Agreements 2010 to 2016

The Global Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies. Trends...

Published:  February 2016
Price:  From

Orphan Drugs - Global Strategic Business Report

This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts...

Published:  April 2015
Price:  From

Global Biosimilars Market, 2015 - 2025

Characterised by increased utility in chronic diseases and capital intensive manufacturing, the global biopharmaceutical market is expanding robustly. As the demand for biologics is increasing continuously,...

Published:  July 2015
Price:  From

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

Published:  May 2015
Price:  From

Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review

Novozymes AS (NZYM B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The...

Published:  July 2015
Price:  From

Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011

Daiichi Sankyo Company, Ltd – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011” provides data...

Published:  November 2011
Price:  From

Industry Report Card: Medicare Cuts Loom As A Senior Factor in U.S. Health Care Company Ratings Oct 11

Abstract Third-party funding of essential care, along with continued high margins for patented medical treatments, has protected many U.S. for-profit health care industry participants from the difficulties...

Published:  October 2011
Price: 

Leukemias - Pipeline Review, H1 2012

Leukemias – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Leukemias - Pipeline Review, H1 2012', provides an overview of the Leukemias therapeutic pipeline. This report provides information...

Published:  January 2012
Price:  From

Industry Report Card: Ratings Outlook Remains Stable For U.S. For-Profit Health Care Companies May 12

Abstract Standard & Poor's Ratings Services expects ratings for 2012 on the U.S. for-profit health care sector to be stable. Our view reflects adequate or better liquidity for a high majority of issuers,...

Published:  May 2012
Price: 

Industry Report Card: A Rash Of Activity For U.S. Speculative-Grade Health Care Companies Jul 10

Abstract With near-term industry visibility improving in the first half of 2010, yield-hungry investors appear to have an increasing interest in the sector's speculative-grade debt issuers. Consequently,...

Published:  July 2010
Price: 

Industry Report Card: The 2011 Credit Prognosis For U.S. Health Care Companies Generally Is Favorable Jan 11

Abstract The prospect for an extended mid-single-digit revenue rise in U.S. health spending remains intact for 2011, based on the ongoing need for largely essential medical goods and services. According...

Published:  January 2011
Price: 

The Protein Therapeutics Market: The Science and Business of a Growing Sector

The protein therapeutics sector is a story of triumphant science, representing both life-saving treatments for millions and a multi-billion dollar industry. This report details both the scientific and...

Published:  June 2006
Price:  From

S&P Extends Deadline For Comments On "Management And Governance" Credit Factors Apr 12

Abstract WASHINGTON D.C. (Standard & Poor's) April 12, 2012Standard & Poor's Ratings Services said today that as a result of significant interest by investors and rated companies, it will extend the...

Published:  April 2012
Price: 

Industry Report Card: Capital Constriction Might Help Stem The Bleeding Of U.S. Corporate Health Care Credit Quality In 2008 Jan 08

Abstract Tight capital market conditions promise to play a pivotal role in U.S. corporate health care creditworthiness in 2008, but possibly in an unexpected way. Specifically, corporate health care...

Published:  January 2008
Price: 

Industry Report Card: Prognosis For North American Health Care Companies Is More Guarded Jul 08

Abstract Now past the midpoint, it appears 2008 is on track to fulfill Standard & Poor's Ratings Services' start-of-the-year expectation for a relatively favorable experience for credit quality in...

Published:  July 2008
Price: 

Industry Report Card: U.S. Health Care Companies Experience Continued Credit Deterioration Jul 07

Abstract Corporate health care issuers' attempts to sustain their favorable operating prospects have been paradoxically accompanied by increased potential for credit deterioration. Capital market conditions...

Published:  July 2007
Price: 

Industry Report Card: North American Health Care Companies Are Resistant, But Not Immune, To Economic Ills Jan 09

Abstract With sustained financial-market turmoil in 2009, a rash of rating cuts for low-speculative-grade health care credits could highlight sector credit pressure more prominently. Along with the...

Published:  January 2009
Price: 
Loading Indicator

Our Clients

  • Glanbia Plc.
  • Unilever N.V.
  • Microsoft Corporation
  • Duke University
  • A.T. Kearney
  • PepsiCo Inc.
  • Boston Consulting Group